19.12USDMkt Cap: 1.06B USDP/E: —Last update: 2026-05-21
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candi…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap1.06B USD
Enterprise Value530.00M USD
Revenue (TTM)8.28M USD
Gross Profit-63.35M USD
Net Income (TTM)-63.73M USD
Revenue/Share0.6480 USD
Last Price19.12 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees79
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-9.74
PEG—
EV/EBITDA-6.91
EV/Revenue64.03
P/S127.69
P/B2.09
EPS (TTM)-1.21
EPS (Forward)-1.96
52W Range
18.4288% of range19.22
52W High19.22 USD
52W Low18.42 USD
Profitability
Gross Margin0.00%
Oper. Margin-703.63%
EBITDA Margin0.00%
Profit Margin-980.93%
ROE43.61%
ROA-24.06%
Growth
Revenue Growth123.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-64.13M USD
CapEx (TTM)9.58M USD
FCF Margin—
FCF Yield—
Net Debt-526.91M USD
Net Debt/EBITDA6.87
Balance Sheet
Debt/Equity-0.08
Current Ratio19.49
Quick Ratio19.37
Book Value/Sh9.156 USD
Cash/Share9.741 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)32.40 USD
Target Range30.00 USD – 34.00 USD
# Analysts5
Ownership
Shares Out.53.40M
Float28.15M
Insiders14.14%
Institutions76.02%
Short Interest
Short Ratio8.1d
Short % Float16.25%
Short % Out.4.65%
Shares Short2.57M
Short (prev mo.)2.32M
Technical
SMA 5018.68 (+2.3%)
SMA 20019.22 (-0.5%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)146.09K
Avg Vol (10d)141.02K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—